Premium
LI‐RADS 2017: An update
Author(s) -
Kielar Ania Z.,
Chernyak Victoria,
Bashir Mustafa R.,
Do Richard K.,
Fowler Kathryn J.,
Mitchell Donald G.,
Cerny Milena,
Elsayes Khaled M.,
Santillan Cynthia,
Kamaya Aya,
Kono Yuko,
Sirlin Claude B.,
Tang An
Publication year - 2018
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.26027
Subject(s) - computer science , terminology , magnetic resonance imaging , bi rads , medical physics , focus (optics) , radiology , hepatocellular carcinoma , medicine , artificial intelligence , cancer , mammography , philosophy , linguistics , physics , breast cancer , optics , cancer research
The computed tomography / magnetic resonance imaging (CT/MRI) Liver Imaging Reporting & Data System (LI‐RADS) is a standardized system for diagnostic imaging terminology, technique, interpretation, and reporting in patients with or at risk for developing hepatocellular carcinoma (HCC). Using diagnostic algorithms and tables, the system assigns to liver observations category codes reflecting the relative probability of HCC or other malignancies. This review article provides an overview of the 2017 version of CT/MRI LI‐RADS with a focus on MRI. The main LI‐RADS categories and their application will be described. Changes and updates introduced in this version of LI‐RADS will be highlighted, including modifications to the diagnostic algorithm and to the optional application of ancillary features. Comparisons to other major diagnostic systems for HCC will be made, emphasizing key similarities, differences, strengths, and limitations. In addition, this review presents the new Treatment Response algorithm, while introducing the concepts of MRI nonviability and viability. Finally, planned future directions for LI‐RADS will be outlined. Level of Evidence: 5 Technical Efficacy: Stage 5 J. Magn. Reson. Imaging 2018;47:1459–1474.